A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

Manipulation of Innate and Adaptive Immunity through Cancer Vaccines

(2017) Elias J. Sayour et al.   Journal of Immunology Research

The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression

(2017) Preeti Singh et al.   NEOPLASIA

Combination immunotherapy: a road map

(2017) Patrick A. Ott et al.   Journal for ImmunoTherapy of Cancer

Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists

(2016) Gregory L. Beatty et al.   Expert Review of Anticancer Therapy

Immuno-oncologists eye up macrophage targets

(2016) Chris Morrison   NATURE REVIEWS DRUG DISCOVERY

Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats

(2015) Cameron G. McCarthy et al.   CARDIOVASCULAR RESEARCH

Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study

(2015) P. Johnson et al.   CLINICAL CANCER RESEARCH

MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

(2015) Burghardt Wittig et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours

(2015) Martin R. Weihrauch et al.   EUROPEAN JOURNAL OF CANCER

PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples

(2015) Boris Winterhoff et al.   EUROPEAN JOURNAL OF CANCER

Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation

(2015) Todd V. Brennan et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunity, inflammation, and cancer: an eternal fight between good and evil

(2015) Shabnam Shalapour et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer

(2015) Susmita Mondal et al.   Oncotarget

Heparanase Cooperates with Ras to Drive Breast and Skin Tumorigenesis

(2014) I. Boyango et al.   CANCER RESEARCH

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma

(2014) D. W. Northfelt et al.   CLINICAL CANCER RESEARCH

Macrophage Polarization in Pancreatic Carcinoma: Role of Heparanase Enzyme

(2014) Esther Hermano et al.   JNCI-Journal of the National Cancer Institute

PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer

(2013) K. T. Ostapoff et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

(2012) J. B. Mitchem et al.   CANCER RESEARCH

Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis

(2012) Vito Ferro et al.   JOURNAL OF MEDICINAL CHEMISTRY

PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model

(2012) Edward Hammond et al.   PLoS One

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

Reparixin, an Inhibitor of CXCR1 and CXCR2 Receptor Activation, Attenuates Blood Pressure and Hypertension-Related Mediators Expression in Spontaneously Hypertensive Rats

(2011) Hye Young Kim et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

(2011) K Dredge et al.   BRITISH JOURNAL OF CANCER

CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2011) C. Zoglmeier et al.   CLINICAL CANCER RESEARCH

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

(2009) Jeffrey S. Weber et al.   CANCER

The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy

(2009) K. Dredge et al.   INVESTIGATIONAL NEW DRUGS

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE